Trials / Completed
CompletedNCT00570882
Study of Sunitinib Administered as 4/2 vs. 2/1 Schedule in Advanced Renal Cell Carcinoma (RCC)
A Randomized Phase II Trial Of Sunitinib Administered Daily For 4 Weeks, Followed By 2-Week Rest Vs. 2-Week On And 1-Week Off In Metastatic Renal Cell Carcinoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 76 (actual)
- Sponsor
- Asan Medical Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is to evaluate the efficacy, safety, and feasibility of sunitinib in 4/2 and 2/1 regimen in previously untreated metastatic RCC to select the most promising regimen, which should be used in further studies of this patient population.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sunitinib 2/1 | Sunitinib 50 mg PO 2 weeks followed by 1 week rest |
| DRUG | Sunitinib 4/2 | Sunitinib 50 mg PO 4 weeks followed by 2 week rest |
Timeline
- Start date
- 2007-10-01
- Primary completion
- 2014-06-01
- Completion
- 2014-06-01
- First posted
- 2007-12-11
- Last updated
- 2014-09-25
Locations
3 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT00570882. Inclusion in this directory is not an endorsement.